Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00892866 · ClinicalTrials.gov registry record · NA

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

A NA study of Human Papillomavirus Infection and Atypical Endometrial Hyperplasia, sponsored by GOG Foundation.

Active
Registry status
NA
Development phase
877
Enrollment target
20
Study locations

NCT00892866 is a NA study of Human Papillomavirus Infection and Atypical Endometrial Hyperplasia that is active but no longer recruiting, run by GOG Foundation. The registered enrollment target is 877 participants, below the 1,267-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00892866, a NA study of Human Papillomavirus Infection and Atypical Endometrial Hyperplasia, is active but no longer recruiting, sponsored by GOG Foundation.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
877 participants
Enrollment target
20
Study locations

Study Summary

This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Cytology Specimen Collection Procedure

Study Locations (20)

Idaho

  • Saint Alphonsus Cancer Care Center-Boise - Boise
  • Saint Alphonsus Cancer Care Center-Caldwell - Caldwell
  • Kootenai Health - Coeur d'Alene - Coeur d'Alene
  • Walter Knox Memorial Hospital - Emmett
  • Idaho Urologic Institute-Meridian - Meridian
  • Saint Alphonsus Medical Center-Nampa - Nampa
  • Kootenai Clinic Cancer Services - Post Falls - Post Falls
  • Kootenai Cancer Clinic - Sandpoint

California

  • UC San Diego Moores Cancer Center - La Jolla
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
  • Saint Joseph Hospital - Orange - Orange
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • Olive View-University of California Los Angeles Medical Center - Sylmar

Arizona

  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Connecticut

  • Hartford Hospital - Hartford
  • The Hospital of Central Connecticut - New Britain

Illinois

  • NorthShore University HealthSystem-Evanston Hospital - Evanston
  • Good Samaritan Regional Health Center - Mount Vernon

Trial Details

FieldValue
Enrollment Target 877 participants
Start Date 2009-04-13
Est. Completion 2025-05-31
Phase NA

Sponsor

GOG Foundation

14 total trials

What the Registry Record Tells You About NCT00892866

The ClinicalTrials.gov registry entry for NCT00892866 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 877 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,267-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (31% lower). The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00892866 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Idaho, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00892866 about?

NCT00892866 is a clinical study titled "CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells". This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effe...

What is the current status of trial NCT00892866?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 877 participants. The study started on 2009-04-13. Estimated completion is 2025-05-31.

What conditions does trial NCT00892866 study?

This clinical trial studies the following conditions: Human Papillomavirus Infection, Atypical Endometrial Hyperplasia, Stage 0 Cervical Cancer AJCC v7.

What interventions are being tested in trial NCT00892866?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).

Who is sponsoring clinical trial NCT00892866?

This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00892866 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Papillomavirus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.